Costimulatory molecule‐<scp>related lncRNA</scp> model as a potential prognostic biomarker in <scp>non‐small</scp> cell lung cancer

Yao, Yuanshan; Yang, Fuzhi; Chen, Anna; Hua, Qingwang; Gao, Wen

doi:10.1002/cam4.5391

Cited by 8 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported that the enrolled 8 TNF-related lncRNAs (LINC01137, LINC02310, AC017100.1, AC108676.1, AC118757.1, AL357873.1, AC104971.3, and HLA-DQB1-AS1) are closely related with cancer progression. LINC01137 has been shown to play an oncogenic role in NSCLC and oral squamous cell carcinoma, which is similar with our results that NSCLC patients with low expression of LINC01137 were likely to exhibit better outcomes ( 32 , 33 ). Zhao et al .…”

Section: Discussionsupporting

confidence: 92%

“…These TNF-related lncRNAs were involved in carcinogenesis, and inflammatory and immune responses ( 22 - 25 ). A number of studies have also demonstrated that some of TNF-related lncRNAs are closely associated with cancer proliferation and survival ( 32 - 38 ). Thus, we analyzed the expression patterns and clinical significance of TNF-related lncRNAs in LUAD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) has become one of the most lethal cancers, for which the recurrence and survival rates remain unfavorable. The tumor necrosis factor (TNF) family is involved in tumorigenesis and tumor progression. Various long non-coding RNAs (lncRNAs) play important roles by mediating the TNF family in cancer. Therefore, this study aimed to construct a TNF-related lncRNA signature to predict prognosis and immunotherapy response in LUAD. Methods:The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.Results: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high-and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy. Conclusions:For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…The secreted lncRNAs act as a messenger and can be packed in extracellular vesicles including exosomes. Recently, the exosomal lncRNAs in patients with cancers had provided both diagnostic and prognostic clues for the management of their malignancies [ 20 , 25 ]. We demonstrated different expression levels of 5 lncRNAs, which have been thought to have oncogenic or tumor suppressor roles in various cancers in the exosomes, ANCT, and tumor tissues of patients with NSCLC.…”

Section: Discussionmentioning

confidence: 99%

“…The gene coding lncRNA-GHSROS is antisense located on the ghrelin receptor encoding a 1.1 kb transcript [ 26 ]. It has been reported that lncRNA-GHSROS is expressed in prostate and breast cancers, and its overexpression is correlated with advanced tumor stages [ 25 , 27 ]. Overexpression of this lncRNA results in increased cellular proliferation and vascularization of tumor tissues [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Expression Analysis of Five Different Long Non-Coding Ribonucleic Acids in Nonsmall-Cell Lung Carcinoma Tumor and Tumor-Derived Exosomes

et al. 2022

View full text Add to dashboard Cite

Long non-coding ribonucleic acids (LncRNAs) are recently known for their role in regulating gene expression and the development of cancer. Controversial results indicate a correlation between the tissue expression of LncRNA and LncRNA content of extracellular vesicles. The present study aimed to evaluate the expression of different LncRNAs in non-small cell lung cancer (NSCLC) patients in tumor tissue, adjacent non-cancerous tissue (ANCT), and exosome-mediated lncRNA. Tumor and ANCT, as well as serum samples of 168 patient with NSCLC, were collected. The GHSROS, HNF1A-AS1, HOTAIR, HMlincRNA717, and LINCRNA-p21 relative expressions in tumor tissue, ANCT, and serum exosomes were evaluated in NSCLC patients. Among 168 NSCLC samples, the expressions of GHSROS (REx = 3.64, p = 0.028), HNF1A-AS1 (REx = 2.97, p = 0.041), and HOTAIR (REx = 2.9, p = 0.0389) were upregulated, and the expressions of HMlincRNA717 (REx = −4.56, p = 0.0012) and LINCRNA-p21 (REx = −5.14, p = 0.00334) were downregulated in tumor tissue in contrast to ANCT. Moreover, similar statistical differences were seen in the exosome-derived RNA of tumor tissues in contrast to ANCT samples. A panel of the five lncRNAs demonstrated that the area under the curve (AUC) for exosome and tumor was 0.937 (standard error: 0.012, p value < 0.0001). LncRNAs GHSROS, HNF1A-AS1, and HOTAIR showed high expression in tumor tissue and exosome content in NSCLC, and a panel that consisted of all five lncRNAs improved diagnosis of NSCLC.

show abstract

Costimulatory molecule‐related lncRNA model as a potential prognostic biomarker in non‐small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Objective: Costimulatory molecules have been demonstrated to exert essential roles in multiple cancers. However, their role in lung cancer remains elusive.Here, we sought to identify costimulatory molecule-related lncRNAs in nonsmall cell lung cancer (NSCLC) and establish a prognostic signature to predict the prognosis of patients with NSCLC.Methods: A total of 535 lung adenocarcinoma (LUAD) and 502 lung squamous cell carcinoma (LUSC) patients from the cancer genome atlas (TCGA) database were recruited. A novel costimulatory molecule-based lncRNA prognostic model was constructed using the least absolute shrinkage and selection operator (LASSO) algorithm to predict the overall survival. The Homo_sapiens.GRCh38 data set was set as a reference file for probe annotation.Results: A total of 593 costimulatory molecule-related lncRNAs were extracted.

show abstract

Costimulatory molecule‐related lncRNA model as a potential prognostic biomarker in non‐small cell lung cancer

Cited by 8 publications

References 67 publications

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Expression Analysis of Five Different Long Non-Coding Ribonucleic Acids in Nonsmall-Cell Lung Carcinoma Tumor and Tumor-Derived Exosomes

Costimulatory molecule‐related lncRNA model as a potential prognostic biomarker in non‐small cell lung cancer

Contact Info

Product

Resources

About